TerminatedObservationalLast updated May 21, 2020

Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)

A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males ≤17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy

Overview

ClinicalTrials.gov ID: NCT02204904
Lead Sponsor: Genetix Biotherapeutics Inc.INDUSTRY
Brief Summary: Study ALD-103 will be a multi-site, global, prospective and retrospective data collection study that is designed to evaluate outcomes of allo-HSCT in male subjects with CALD ≤17 years of age.
Study Type: Observational

Status

Overall Status: Terminated
Start Date: Apr 2015Actual
Primary Completion Date: Dec 6, 2019Actual
Completion Date: Dec 6, 2019Actual

Study Record Dates

First Submitted: Jul 28, 2014
First Submitted that Met QC Criteria: Jul 29, 2014
First Posted: Jul 31, 2014Estimated
Last Update Submitted that Met QC Criteria: May 19, 2020
Last Update Posted: May 21, 2020Actual
Last Verified: Dec 2019

NCT03852498Completed

A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

NCT01896102Completed

A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

NCT04528706Unknown status

A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)

NCT06224413Recruiting

A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene Autotemcel

NCT06030648Suspended

MT2022-01: MSCs for ALD

NCT03278899Unknown status

A Study to Prospectively Assess Disease Progression in Male Children With X-ALD